Article
Dermatology
Fabio Verardi, Lara Valeska Maul, Kim Borsky, Simona Steinmann, Nina Rosset, Hector Ortega Pons, Christina Sorbe, Nikhil Yawalkar, Raphael Micheroli, Alexander Egeberg, Jacob P. Thyssen, Kristine Heidemeyer, Wolf-Henning Boehncke, Curdin Conrad, Antonio Cozzio, Andreas Pinter, Thomas Kundig, Alexander A. Navarini, Julia-Tatjana Maul
Summary: This study aims to examine the long-term safety of systemic psoriasis therapies and analyze the occurrence of adverse events in male and female patients. The study found that female patients had higher rates of adverse events and drug-related discontinuation, suggesting the importance of considering sex stratification in the management of psoriasis.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Pharmacology & Pharmacy
Vito Di Lernia, Laura Macca, Lucia Peterle, Ylenia Ingrasciotta, Gianluca Trifiro, Claudio Guarneri
Summary: The study found that biological therapies may provide short-term efficacy for moderate-to-severe psoriasis in children. The probability of achieving PASI 75 and PASI 90 was higher for IL-12/23 and IL-17 inhibitors, with a more favorable NNT. Therefore, these systemic drugs may be beneficial for treating plaque psoriasis in children and adolescents.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Infectious Diseases
Clemence Lacroix, Annie-Pierre Bera-Jonville, Francois Montastruc, Lionel Velly, Joelle Micallef, Romain Guilhaumou
Summary: The study analyzed the largest case series of serious CNS adverse drug reactions induced by ceftriaxone, identifying common symptoms including convulsions, myoclonia, and confusion, mainly in elderly female patients. It suggests caution in the use of ceftriaxone, particularly in older patients or those with renal impairment.
Review
Dermatology
Brent J. Doolan, Digsu Koye, Joanna Ling, Geoffrey D. Cains, Christopher Baker, Peter Foley, Con Dolianitis
Summary: This study conducted a retrospective observational study on the data from the Australasian Psoriasis Registry, revealing that biologic therapy may increase the risk of infections, cardiac, gastrointestinal, hepatobiliary, psychiatric, and eye disorders in patients who are ineligible for clinical trials.
AUSTRALASIAN JOURNAL OF DERMATOLOGY
(2021)
Article
Anesthesiology
Efe Eworuke, Leah Crisafi, Jiemin Liao, Sandia Akhtar, Martha Van Clief, Judith A. Racoosin, Michael Wernecke, Thomas E. MaCurdy, Jeffrey A. Kelman, David J. Graham
Summary: Between 2009 and 2015, rates of SSAEs following ESI in the Medicare population were low. Patients receiving cervical/thoracic ESIs were at higher risk of SSAE than those receiving lumbar/sacral ESIs. Event rates were similar for each corticosteroid formulation.
REGIONAL ANESTHESIA AND PAIN MEDICINE
(2021)
Review
Anesthesiology
Sander Kempenaers, Tom G. Hansen, Marc van de Velde
Summary: Remimazolam is an interesting anaesthetic and sedative that combines the pharmacodynamic properties of midazolam with pharmacokinetic properties similar to remifentanil. However, recent case reports of anaphylaxis, delayed emergence, and re-sedation have raised concerns and require further investigation.
EUROPEAN JOURNAL OF ANAESTHESIOLOGY
(2023)
Review
Anesthesiology
Adrienne K. Ho, Anthony M-H Ho, Tim Cooksley, Giang Nguyen, Jason Erb, Glenio B. Mizubuti
Summary: Immune checkpoint inhibitors are a new treatment modality for cancer that can restore antitumor immunity by blocking the binding of cancer cell proteins to T-cell checkpoints. However, they may also lead to immune-related adverse events, including autoimmune complications.
ANESTHESIA AND ANALGESIA
(2021)
Review
Biochemistry & Molecular Biology
Rose Parisi, Hemali Shah, Neil H. Shear, Michael Ziv, Alina Markova, Roni P. Dodiuk-Gad
Summary: The rapid development of anti-cancer therapy has improved treatment outcomes for cancer patients, but it has also been associated with the occurrence of bullous dermatologic adverse events (DAE), which can negatively impact patients' quality of life and treatment continuation. Effective management of these adverse events is crucial for minimizing treatment interruptions and maintaining the anti-tumor effect.
Review
Immunology
Jiao Wang, Chunxiao Wang, Liu Liu, Seokgyeong Hong, Yi Ru, Xiaoying Sun, Jiale Chen, Miao Zhang, Naixuan Lin, Bin Li, Xin Li
Summary: This systematic review and meta-analysis aimed to summarize the number and rates of adverse events caused by anti-IL-17 biological agents in patients with psoriasis and psoriatic arthritis. The study found that the use of anti-IL-17 biological agents was associated with a high incidence of adverse events, but the symptoms were generally mild.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Medicinal
Lukas Kraehenbuehl, Stephanie Schneider, Laura Pawlik, Joanna Mangana, Phil Cheng, Reinhard Dummer, Barbara Meier-Schiesser
Summary: Recent progress in the treatment of advanced melanoma has led to improved survival, but also increased skin toxicity. This study investigated biopsy-proven cutaneous adverse events in melanoma treatment over 10 years. Skin adverse events were more common with targeted therapies compared to immune checkpoint blockade. A wide range of skin adverse events were observed, with different types associated with specific treatment classes.
Article
Computer Science, Artificial Intelligence
Bruno Perez, Christophe Lang, Julien Henriet, Laurent Philippe, Frederic Auber
Summary: The study focuses on managing risks related to the elements in an operating room, proposing an architecture that combines MAS with CBR. This approach allows for efficient analysis and prediction of system state, as well as determination of alert thresholds and risk prediction.
EXPERT SYSTEMS WITH APPLICATIONS
(2021)
Article
Immunology
Lin Zhao, Yan Zeng, Lin Sun, Zenglei Zhang, Kunqi Yang, Zuozhi Li, Man Wang, Xianliang Zhou, Weixian Yang
Summary: Elevated fibrinogen levels are associated with adverse clinical events in patients with psoriasis and coronary artery disease (CAD), especially among patients aged <60 years, those with diabetes, and those not admitted for acute cardiovascular syndrome.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Review
Oncology
Katrin Madjar, Rajat Mohindra, Gonzalo Duran-Pacheco, Rashad Rasul, Laurent Essioux, Vidya Maiya, G. Scott Chandler
Summary: A post-hoc meta-analysis using data from 15 Roche sponsored clinical trials with atezolizumab revealed baseline risk factors associated with the onset of immune-related adverse events (irAEs). The study aims to optimize the benefit/risk balance in patients receiving cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Allergy
Jamie L. Waldron, Stephen A. Schworer, Mildred Kwan
Summary: Biologic medications are a growing field of therapeutics for cancer and inflammatory diseases, known for their targeted approach and reduced toxicity compared to traditional systemic medications. However, with increased usage, adverse effects from biologic administration have become more apparent, including immune-related toxicities and immediate or delayed hypersensitivity reactions.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
S. Veerasuri, D. Little, K. N. De Paepe, A. Andreou, R. Bowen, M. Beresford, T. Tillett, S. Gangadhara, W. W. Loughborough
Summary: In the past decade, there has been a paradigm shift in medical oncology treatment with the emergence of molecular targeted therapy and immunotherapy. These novel systemic agents have improved prognosis for certain patient cohorts with advanced disease, and ongoing clinical research aims to demonstrate significant survival benefits across various tumor types. Radiological response assessment of these new agents has become more complex, and radiologists must be vigilant of potential adverse events associated with the treatments.
CLINICAL RADIOLOGY
(2021)
